我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
123
20 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中(未招募)
8
6.5%
已完成
67
54.5%
Enrolling By Invitation
2
1.6%
尚未招募
10
8.1%
招募中
14
11.4%
暂停
1
0.8%
终止
Unknown
19
15.4%
暂无批准数据
- A real-world study of 75,491 influenza patients found that Xofluza (baloxavir) significantly reduced hospitalization rates compared to Tamiflu (oseltamivir) across multiple time points. - At six months post-treatment, hospitalization rates were 0.8% for Xofluza versus 5.3% for Tamiflu, while emergency department visits were 5% versus 7.2% respectively. - The superior outcomes were most pronounced in female patients and those under 50 years of age, with no significant difference in mortality rates between treatments. - Researchers suggest baloxavir may help alleviate healthcare system burden during influenza seasons through reduced downstream complications requiring medical intervention.